Prelude Therapeutics Inc (PRLD) - Net Assets
Based on the latest financial reports, Prelude Therapeutics Inc (PRLD) has net assets worth $58.53 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.75 Million) and total liabilities ($36.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRLD asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $58.53 Million |
| % of Total Assets | 61.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -38.04% |
| 10-Year Change | N/A |
| Growth Volatility | 33.71 |
Prelude Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Prelude Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Prelude Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for Prelude Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Prelude Therapeutics Inc from 2018 to 2024. For live valuation and market cap data, see Prelude Therapeutics Inc (PRLD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $131.46 Million | -44.55% |
| 2023-12-31 | $237.09 Million | +21.31% |
| 2022-12-31 | $195.44 Million | -31.64% |
| 2021-12-31 | $285.90 Million | +34.74% |
| 2020-12-31 | $212.18 Million | +529.42% |
| 2019-12-31 | $-49.41 Million | -117.74% |
| 2018-12-31 | $-22.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prelude Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56063600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $35.00K | 0.03% |
| Other Components | $714.98 Million | 543.88% |
| Total Equity | $131.46 Million | 100.00% |
Prelude Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Prelude Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tai-Saw Technology Co Ltd
TWO:3221
|
$140.21 Million |
|
Bastogi S.p.A
F:BAOA
|
$140.24 Million |
|
SEEING MACHINES LTD
F:M2Z
|
$140.28 Million |
|
CB Industrial Product Holding
KLSE:7076
|
$140.33 Million |
|
Uno&Company.Ltd
KQ:114630
|
$140.17 Million |
|
PT Indonesia Kendaraan Terminal Tbk
JK:IPCC
|
$140.11 Million |
|
Innoviz Technologies
NASDAQ:INVZ
|
$140.09 Million |
|
BriQ Properties Real Estate Investment Company
AT:BRIQ
|
$140.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prelude Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 237,090,000 to 131,459,000, a change of -105,631,000 (-44.6%).
- Net loss of 127,173,000 reduced equity.
- Other comprehensive income decreased equity by 188,000.
- Other factors increased equity by 21,730,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-127.17 Million | -96.74% |
| Other Comprehensive Income | $-188.00K | -0.14% |
| Other Changes | $21.73 Million | +16.53% |
| Total Change | $- | -44.55% |
Book Value vs Market Value Analysis
This analysis compares Prelude Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-14.40 | $4.70 | x |
| 2019-12-31 | $-1.52 | $4.70 | x |
| 2020-12-31 | $4.85 | $4.70 | x |
| 2021-12-31 | $6.01 | $4.70 | x |
| 2022-12-31 | $4.13 | $4.70 | x |
| 2023-12-31 | $3.93 | $4.70 | x |
| 2024-12-31 | $1.73 | $4.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prelude Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -96.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1816.76%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.34x
- Recent ROE (-96.74%) is below the historical average (-38.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.41 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.63 Million |
| 2020 | -26.83% | 0.00% | 0.00x | 1.05x | $-78.15 Million |
| 2021 | -38.75% | 0.00% | 0.00x | 1.07x | $-139.37 Million |
| 2022 | -54.92% | 0.00% | 0.00x | 1.13x | $-126.88 Million |
| 2023 | -51.39% | 0.00% | 0.00x | 1.17x | $-145.54 Million |
| 2024 | -96.74% | -1816.76% | 0.04x | 1.34x | $-140.32 Million |
Industry Comparison
This section compares Prelude Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prelude Therapeutics Inc (PRLD) | $58.53 Million | 0.00% | 0.62x | $140.19 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more